{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:24:43Z","timestamp":1765430683649,"version":"3.46.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The BRAF V600E mutation in papillary thyroid carcinoma (PTC) is linked to aggressive behavior and frequent occult central lymph node metastases (CLNM), posing a surgical dilemma in clinically node-negative (cN0) patients. Sentinel lymph node biopsy (SLNB) could enable selective intervention, but its accuracy depends on tracer performance. We investigated the utility of SLNB using mitoxantrone hydrochloride injection (MHI) as a novel lymphatic tracer to determine its feasibility and diagnostic performance for occult metastases in patients with cN0, BRAF V600E\u2013mutated, unilateral PTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>48 patients with cN0, BRAF V600E-mutated unilateral PTC underwent intraoperative SLNB using MHI, followed by ipsilateral lobectomy with isthmusectomy and prophylactic central neck dissection (PCND). The diagnostic accuracy of SLNB was evaluated by comparing its results with the final histological results from PCND serving as the gold standard. Short-term postoperative complications were recorded to assess the safety of the procedure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sentinel lymph nodes (SLNs) were identified in 46 out of 48 patients (95.8%), with 62 SLNs retrieved, most commonly in the peritracheal region (93.5%). Intraoperative frozen section analysis identified 21 patients with positive SLNs and 25 with negative SLNs. Final pathology confirmed CLNM in 23 patients (47.9%). The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of SLNB for detecting CLNM were 91.3%, 100%, 92.6%, and 100%, respectively. Postoperatively, two patients (4.2%) experienced transient vocal cord palsy, with complete resolution within one week. No cases of parathyroid injury or removal were observed, and there were no instances of transient hypoparathyroidism or permanent complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with cN0, BRAF V600E\u2013mutated PTC, SLNB using mitoxantrone hydrochloride injection is technically feasible and demonstrates high sensitivity and specificity. This approach may help identify individuals with occult central compartment metastases, thereby potentially avoiding unnecessary PCND in those with negative SLNs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1732034","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:19:41Z","timestamp":1765430381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitoxantrone hydrochloride injection guided sentinel lymph node biopsy in cN0 BRAF V600E-mutated papillary thyroid carcinoma: a feasibility study"],"prefix":"10.3389","volume":"16","author":[{"given":"Zengwei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingfei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Men","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0045","article-title":"Progress in thyroid cancer genomics: A 40-year journey","volume":"33","author":"Fagin","year":"2023","journal-title":"Thyroid\u00ae"},{"key":"B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12022-011-9184-5","article-title":"BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion","volume":"23","author":"Chakraborty","year":"2011","journal-title":"Endocr Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0607","article-title":"BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0110","article-title":"The synergic effect of BRAFV600E mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma","volume":"65","author":"Qu","year":"2018","journal-title":"Endocr J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.32725\/jab.2024.025","article-title":"BRAF V600E positive papillary thyroid carcinoma (TERT and TP53 mutation coexistence excluded): Correlation of clinicopathological features and the extent of surgical treatment and its complications","volume":"22","author":"Hlo\u017eek","year":"2024","journal-title":"J Appl Biomed"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2741\/4359","article-title":"The role of BRAF in the pathogenesis of thyroid carcinoma","volume":"20","author":"Li","year":"2015","journal-title":"Front Biosci-Landmark"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/gs-20-244","article-title":"BRAF V600E mutation correlates with aggressive clinico-pathological features but does not influence tumor recurrence in papillary thyroid carcinoma\u201410-year single-center results","volume":"9","author":"Tabriz","year":"2020","journal-title":"Gland Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12022-025-09859-y","article-title":"Prevalence and clinical impact of BRAF p.V600E mutation in papillary thyroid carcinoma","volume":"36","author":"Brumfield","year":"2025","journal-title":"Endocr Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/cancers16010113","article-title":"The impact of BRAF V600E mutation allele frequency on the histopathological characteristics of thyroid cancer","volume":"16","author":"Abdulhaleem","year":"2023","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2016.02.001","article-title":"Prophylactic central neck dissection might not be necessary in papillary thyroid carcinoma: analysis of 11,569 cases from a single institution","volume":"222","author":"Kim","year":"2016","journal-title":"J Am Coll Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"109258","DOI":"10.1016\/j.surg.2025.109258","article-title":"Prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma: 10-year impact on surgical and oncologic outcomes","volume":"181","author":"Papini","year":"2025","journal-title":"Surgery"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3390\/biomedicines12102177","article-title":"Central neck dissection in papillary thyroid carcinoma: benefits and doubts in the era of thyroid lobectomy","volume":"12","author":"Zocchi","year":"2024","journal-title":"Biomedicines"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.8985","article-title":"Prophylactic central neck dissection for papillary thyroid cancer","volume":"100","author":"Barczy\u0144ski","year":"2013","journal-title":"J Br Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0608","article-title":"A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy","volume":"23","author":"Lang","year":"2013","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2017.01.113","article-title":"Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center","volume":"41","author":"Dobrinja","year":"2017","journal-title":"Int J Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2021.02.035","article-title":"Prophylactic central neck dissection in papillary thyroid carcinoma: all risks, no reward","volume":"264","author":"Dismukes","year":"2021","journal-title":"J Surg Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1208\/s12249-019-1447-3","article-title":"A novel self-assembly nanocrystal as lymph node-targeting delivery system: higher activity of lymph node targeting and longer efficacy against lymphatic metastasis","volume":"20","author":"Mao","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.914057","article-title":"Efficacy and safety of mitoxantrone hydrochloride injection for tracing axillary sentinel nodes in breast cancer: A self-controlled clinical trial","volume":"12","author":"Jiao","year":"2022","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2020.11.023","article-title":"Incidental parathyroidectomy in thyroidectomy and central neck dissection","volume":"169","author":"Barrios","year":"2021","journal-title":"Surgery"},{"key":"B22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0889-8529(03)00009-4","article-title":"Prevention, evaluation, and management of complications following thyroidectomy for thyroid carcinoma","volume":"32","author":"Zarnegar","year":"2003","journal-title":"Endocrinol Metab Clinics North America"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1732034\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:19:42Z","timestamp":1765430382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1732034\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":22,"alternative-id":["10.3389\/fendo.2025.1732034"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1732034","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"article-number":"1732034"}}